| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Cleavable Linker
Boc‑Val‑Dil‑Dap‑OH itself does not have a pharmacological target; instead, it serves as a protease‑cleavable linker scaffold in ADC design. The valine (Val) and Dil (dolaisoleucine) residues are designed to be recognized and cleaved by lysosomal cathepsin enzymes following ADC internalization into target cancer cells, releasing the conjugated payload. |
|---|---|
| ln Vitro |
ADCs are made up of an antibody and an ADC cytotoxin that are joined together by an ADC linker.
Not applicable. Boc‑Val‑Dil‑Dap‑OH is a synthetic building block for ADC construction and exhibits no direct biological activity independent of its conjugation to antibodies and cytotoxins. Its in vitro utility is assessed via successful conjugation efficiency and stability in plasma rather than direct target inhibition or cell killing. |
| ln Vivo |
Not applicable. Boc‑Val‑Dil‑Dap‑OH is not administered in vivo as a standalone compound. Rather, it is incorporated into an ADC molecule via chemical synthesis. The in vivo performance of ADCs built with this linker is evaluated in mouse xenograft models to measure tumor‑targeted payload delivery, efficacy, and safety, but Boc‑Val‑Dil‑Dap‑OH alone has no in vivo activity.
|
| Enzyme Assay |
Not applicable; Boc‑Val‑Dil‑Dap‑OH is a chemical linker and is not evaluated in enzyme/receptor binding assays. Instead, the peptide linker structure can be incorporated into a model fluorogenic peptide substrate to demonstrate cleavage by lysosomal cathepsins in vitro, but this is not a standard “assay” for the linker itself.
|
| Cell Assay |
Not applicable; Boc‑Val‑Dil‑Dap‑OH is not tested directly on cells. However, functional validation of ADCs synthesized using this linker involves incubating the complete ADC with antigen‑positive cancer cells. Following ADC internalization, linker cleavage and payload release are assessed by measuring cytotoxin‑induced cell death (e.g., CellTiter‑Glo viability assays) or by mass spectrometry detection of released payload in cell lysates.
|
| Animal Protocol |
Not applicable; Boc‑Val‑Dil‑Dap‑OH is not used as an independent compound in animal studies. ADCs incorporating this linker are evaluated in mouse xenograft tumor models by administering the ADC (e.g., 1-10 mg/kg, i.v.) once weekly for 2-4 weeks. Efficacy endpoints include tumor volume inhibition (TGI %), while safety is monitored via body weight and serum chemistry.
|
| ADME/Pharmacokinetics |
Not applicable; Boc‑Val‑Dil‑Dap‑OH is a chemical intermediate not intended for in vivo administration as a therapeutic. Pharmacokinetic properties are determined for the final ADC molecule, not for the isolated linker. In general, ADCs built with protease‑cleavable Val‑Dil‑type linkers display low systemic release of free payload in circulation, contributing to a favorable pharmacokinetic profile (low clearance, extended half‑life) for the ADC.
|
| Toxicity/Toxicokinetics |
Not applicable; Boc‑Val‑Dil‑Dap‑OH is not a drug substance and is not tested in standalone toxicology studies. Safety assessments are conducted on the final ADC molecule. Toxicity of ADCs using Boc‑Val‑Dil‑Dap‑OH may include on‑target payload‑mediated effects (e.g., neutropenia, peripheral neuropathy) depending on the conjugated cytotoxin, as well as off‑target cleavage‑related toxicities.
|
| References |
[1]. Céline Mordant, et al. Total synthesis of dolastatin 10 through ruthenium-catalyzed asymmetric hydrogenations. Tetrahedron. Volume 63, Issue 27, 2 July 2007, Pages 6115-6123.
|
| Additional Infomation |
Boc‑Val‑Dil‑Dap‑OH is strictly a research‑grade synthetic building block used for the custom synthesis of antibody‑drug conjugates (ADCs). It is not a therapeutic agent and has not been approved for human use. The compound is valuable for medicinal chemistry research focusing on next‑generation ADC linkers with improved hydrophilicity, stability, and controlled payload release.
|
| Molecular Formula |
C29H53N3O8
|
|---|---|
| Exact Mass |
571.383
|
| CAS # |
1415246-54-6
|
| PubChem CID |
71109643
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
40
|
| Complexity |
859
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)OC(C)(C)C
|
| InChi Key |
OCXHPHOVIMNVPQ-UTHKHBGESA-N
|
| InChi Code |
InChI=1S/C29H53N3O8/c1-12-18(4)24(31(9)26(34)23(17(2)3)30-28(37)40-29(6,7)8)21(38-10)16-22(33)32-15-13-14-20(32)25(39-11)19(5)27(35)36/h17-21,23-25H,12-16H2,1-11H3,(H,30,37)(H,35,36)/t18-,19+,20-,21+,23-,24-,25+/m0/s1
|
| Chemical Name |
(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (174.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
